Immunity to adeno-associated virus vectors in animals and humans: A continued challenge

Gene Therapy

Volumn 15, Issue 11, 2008, Pages 808-816

  Zaiss, A K ^a   Muruve, D A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 9; COMPLEMENT COMPONENT C3B; CYCLOSPORIN; DACLIZUMAB; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN; MALARIA VACCINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORNITHINE CARBAMOYLTRANSFERASE; PARVOVIRUS VECTOR; RAPAMYCIN; RETINOIC ACID INDUCIBLE PROTEIN I; TACROLIMUS; THYMOCYTE ANTIBODY; VIRUS ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADAPTIVE IMMUNITY; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY PRODUCTION; CELLULAR IMMUNITY; CLINICAL TRIAL; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME REPLACEMENT; GENE EXPRESSION; GENETIC TRANSDUCTION; HEMOPHILIA B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOLOGY; INNATE IMMUNITY; MALARIA; MEMORY T LYMPHOCYTE; NONHUMAN; PARVOVIRUS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; TRANSGENE; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS IMMUNITY; VIRUS MUTATION;

ANIMALS; ANTIBODIES, VIRAL; CAPSID PROTEINS; DEPENDOVIRUS; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; IMMUNITY, NATURAL; T-LYMPHOCYTES, REGULATORY; TRANSGENES;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MIRIDAE;

EID: 44049083209     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.54     Document Type: Review

References (95)

1. Samulski RJ, Berns KI, Tan M, Muzyczka N Cloning of adeno-associated virus into pBR322: Rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci USA 1982; 79: 2077-2081.
2. Duan D, Sharma P, Yang J, Yue Y, Dudus L, Zhang Y et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 1998; 72: 8568-8577.
3. Nakai H, Yant SR, Storm TA, Fuess S, Meuse L, Kay MA. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 2001; 75: 6969-6976.
4. Gao G, Lu Y, Calcedo R, Grant RL, Bell P, Wang L et al. Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther 2006; 13: 77-87.
5. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854-11859.
6. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 1999; 5: 71-77.
7. Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5 integrin: A co-receptor for adeno-associated virus type 2 infection. Nat Med 1999; 5: 78-82.
8. Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A et al. Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 2003; 9: 1306-1312.
9. Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol 2006; 80: 9831-9836.
10. Lai Y, Yue Y, Liu M, Ghosh A, Engelhardt JF, Chamberlain JS et al. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol 2005; 23: 1435-1439.
11. Miller DG, Wang PR, Petek LM, Hirata RK, Sands MS, Russell DW. Gene targeting in vivo by adeno-associated virus vectors. Nat Biotechnol 2006; 24: 1022-1026.
12. Vasileva A, Jessberger R. Precise hit: Adeno-associated virus in gene targeting. Nat Rev Microbiol 2005; 3: 837-847.
13. Mount JD, Herzog RW, Tillson DM, Goodman SA, Robinson N, McCleland ML et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 2002; 99: 2670-2676.
14. Mas A, Montane J, Anguela XM, Munoz S, Douar AM, Riu E et al. Reversal of type 1 diabetes by engineering a glucose sensor in skeletal muscle. Diabetes 2006; 55: 1546-1553.
15. Jiang H, Lillicrap D, Patarroyo-White S, Liu T, Qian X, Scallan CD et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 2006; 108: 107-115.
16. Jiang H, Pierce GF, Ozelo MC, de Paula EV, Vargas JA, Smith P et al Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther 2006; 14: 452-455.
17. Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan JC, Garcia L et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 2004; 306: 1796-1799.
18. Acland GM, Aguirre GD, Bennett J, Aleman TS, Cideciyan AV, Bennicelli J et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 2005; 12: 1072-1082.
19. Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nat Immunol 2004; 5: 971-974.
20. Meylan E, Tschopp J. Toll-like receptors and RNA helicases: Two parallel ways to trigger antiviral responses. Mol Cell 2006; 22: 561-569.
21. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006; 442: 39-44.
22. Hensley SE, Amalfitano A. Toll-like receptors impact on safety and efficacy of gene transfer vectors. Mol Ther 2007; 15: 1417-1422.
23. Rautsi O, Lehmusvaara S, Salonen T, Hakkinen K, Sillanpaa M, Hakkarainen T et al. Type I interferon response against viral and non-viral gene transfer in human tumor and primary cell lines. J Gene Med 2007; 9: 122-135.
24. Chen H, Lilley CE, Yu Q, Lee DV, Chou J, Narvaiza I et al. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol 2006; 16: 480-485.
25. Harris RS, Liddament MT. Retroviral restriction by APOBEC proteins. Nat Rev Immunol 2004; 4: 868-877.
26. Zaiss AK, Liu Q, Bowen GP, Wong NC, Bartlett JS, Muruve DA. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 2002; 76: 4580-4590.
27. Zaiss AK, Cotter MJ, White M Clark SA, Wong NC, Holers VM et al. Complement is an essential component of the immune response to adeno-associated virus vectors. J Virol 2008; 82: 2727-2740.
28. Lutz HU, Jelezarova E. Complement amplification revisited. Mol Immunol 2006; 43: 2-12.
29. Schneider MC, Exley RM, Chan H, Feavers I, Kang YH, Sim RB et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 2006; 176: 7566-7575.
30. Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol 2004; 5: 981-986.
31. Carroll MC. The complement system in B cell regulation. Mol Immunol 2004; 41: 141-146.
32. Kemper C, Atkinson JP. T-cell regulation: With complements from innate immunity. Nat Rev Immunol 2007; 7: 9-18.
33. Gao G, Lebherz C, Weiner DJ, Grant R, Calcedo R, McCullough B et al Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 2004; 103: 3300-3302.
34. Chenuaud P, Larcher T, Rabinowitz JE, Provost N, Cherel Y, Casadevall N et al. Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 2004; 103: 3303-3304.
35. Greelish JP, Su LT, Lankford EB, Burkman JM, Chen H, Konig SK et al Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med 1999; 5: 439-443.
36. Herzog RW, Hagstrom JN, Kung SH, Tai SJ, Wilson JM, Fisher KJ et al Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997; 94: 5804-5809.
37. Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA et al Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5: 56-63.
38. Jooss K, Yang Y, Fisher KJ, Wilson JM. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72: 4212-4223.
39. Wang L, Takabe K, Bidlingmaier SM, Ill CR, Verma IM. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci USA 1999; 96: 3906-3910.
40. Snyder RO, Spratt SK, Lagarde C, Bohl D, Kaspar B, Sloan B et al. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther 1997; 8: 1891-1900.
41. Manning WC, Paliard X, Zhou S, Pat Bland M, Lee AY, Hong K et al. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. J Virol 1997; 71: 7960-7962.
42. Sarukhan A, Camugli S, Gjata B, von Boehmer H, Danos O, Jooss K. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors. J Virol 2001; 75 269-277.
43. Herzog RW, Fields PA, Arruda VR, Brubaker JO, Armstrong E, McClintock D et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther 2002; 13: 1281-1291.
44. Cordier L, Gao GP, Hack AA, McNally EM, Wilson JM, Chirmule N et al Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther 2001; 12: 205-215.
45. Ziegler RJ, Lonning SM, Armentano, D, Li C, Souza DW, Cherry M et al AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice. Mol Ther 2004; 9: 231-240.
46. Franco LM, Sun B, Yang X, Bird A, Zhang H, Schneider A et al. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther 2005; 12: 876-884.
47. Mingozzi F, Liu YL, Dobrzynski E, Kaufhold A, Liu JH, Wang Y et al Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 2003; 111: 1347-1356.
48. Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, Edmonson SA, Hui DJ, Sabatino DE et al. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 2007; 110: 23334-234l.
49. Wang L, Cao O, Swalm B, Dobrzynski E, Mingozzi F, Herzog RW. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Therapy 2005; 12: 1453-1464.
50. Jiang H, Couto LB, Patarroyo-White S, Liu T, Nagy D, Vargas JA et al Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 2006; 108: 3321-3328.
51. Moscioni D, Morizono H, McCarter RJ, Stern A, Cabrera-Luque J, Hoang A et al. Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors. Mol Ther 2006; 14: 25-33.
52. Lozier JN, Metzger ME, Donahue RE, Morgan RA. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity. Blood 1999; 94: 3968-3975.
53. Dobrzynski E, Mingozzi F, Liu YL, Bendo E, Cao O, Wang L et al. Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer. Blood 2004; 104: 969-977.
54. Cao O, Dobrzynski E, Wang L, Nayak S, Mingle B, Terhorst C et al. Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood 2007; 110: 1132-1140.
55. Sun B, Bird A, Young SP, Kishnani PS, Chen YT, Koeberl DD. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am J Hum Genet 2007; 81: 1042-1049.
56. Hoffman BE, Dobrzynski E, Wang L, Hirao L, Mingozzi F, Cao O et al Muscle as a target for supplementary factor IX gene transfer. Hum Gene Ther 2007; 18: 603-613.
57. Xin KQ, Urabe M, Yang J, Nomiyama K, Mizukami H, Hamajima K et al. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum Gene Ther 2001; 12: 1047-1061.
58. Johnson PR, Schnepp BC, Connell MJ, Rohne D, Robinson S, Krivulka GR et al. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 2005; 79: 955-965.
59. Xin KQ Mizukami H, Urabe M, Toda. Y, Shinoda K, Yoshida A et al. Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells. J Virol 2006; 80: 11899-11910.
60. Lin J, Zhi Y, Mays L, Wilson JM. Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice. J Virol 2007; 81: 11840-11849.
61. Lin SW, Hensley SE, Tatsis N, Lasaro MO, Ertl HC. Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8 T cells in mice. J Clin Invest 2007; 117 3958-3970.
62. Logan GJ, Wang L, Zheng M, Cunningham SC, Coppel RL, Alexander IE. AAV vectors encoding malarial antigens stimulate antigen-specific immunity but do not protect from parasite infection. Vaccine 2007; 25 1014-1022.
63. Scallan CD, Jiang H, Liu T, Patarroyo-White S, Sommer JM, Zhou S et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 2006; 107 1810-1817.
64. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
65. Halbert CL, Standaert TA, Wilson CB, Miller AD. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J Virol 1998; 72: 9795-9805.
66. Chirmule N, Xiao W, Trumeh A, Schnell MA, Hughes JV, Zoltick P et al Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol 2000; 74: 2420-2425.
67. Murphy SL, Li H, Zhou S, Schlachterman A, High K. Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver. Mol Ther 2008; 16: 138-145.
68. Lochne MA, Tatsuno GP, Christie B, McDonnell JW, Zhou S, Surosky R, et al. Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J Virol 2006; 80: 821-834.
69. Huttner NA, Girod A, Perabo L, Edbauer D, Kleinschmidt JA, Buning H et al. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Therapy 2003; 10: 2139-2147.
70. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 2006; 24: 198-204.
71. Peden CS, Burger C, Muzyczka N, Mandel RJ. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol 2004; 78: 6344-6359.
72. Grimm D, Kay MA. From virus evolution to vector revolution: Use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 2003; 3: 281-304.
73. Riviere C, Danos O, Douar AM. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Therapy 2006; 13: 1300-1308.
74. Nathwani AC, Gray JT, McIntosh J, Ng CY, Zhou J, Spence Y et al. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 2007; 109 1414-1421.
75. Halbert CL, Miller AD, McNamara S, Emerson J, Gibson RL, Ramsey B et al. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: implications for gene therapy using AAV vectors. Hum Gene Ther 2006; 17: 440-447.
76. De BP, Heguy A, Hackett NR, Ferris B, Leopold PL, Lee J et al. High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. Mol Ther 2006; 13: 67-76.
77. Arbetman AE, Lochrie M, Zhou S, Wellman J, Scallan C, Doroudchi MM et al. Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties. J Virol 2005; 79: 15238-15245.
78. Limberis MP, Wilson JM. Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. Proc Natl Acad Sci USA 2006; 103: 12993-12998.
79. Nathwani AC, Davidoff AM, Hanawa H, Hu Y, Hoffer FA, Nikanorov A et al. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood 2002; 100: 1662-1669.
80. Snyder RO. Adeno-associated virus-mediated gene delivery. J Gene Med 1999; 1: 166-175.
81. Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE et al CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007; 13: 419-422.
82. Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 2000; 105: 1573-1587.
83. Yan Z, Zak R, Luxton GW, Ritchie TC, Bantel-Schaal U, Engelhardt JF. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J Virol 2002; 76: 2043-2053.
84. Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther 2007; 7: 316-324.
85. Li C, Hirsch M, Asokan A, Zeithaml B, Ma H, Kafri T et al. Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. J Virol 2007; 81: 7540-7547.
86. Li H, Murphy SL, Giles-Davis W, Edmonson S, Xiang Z, Li Y et al. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther 2007; 15: 792-800.
87. Vandenberghe LH, Wilson JM. AAV as an immunogen. Curr Gene Ther 2007; 7: 325-333.
88. Sabatino DE, Mingozzi F, Hui DJ, Chen H, Colosi P, Ertl HC et al. Identification of mouse AAV capsid-specific CD8+ T cell epitopes. Mol Ther 2005; 12: 1023-1033.
89. Vandenberghe LH, Wang L, Somanathan S, Zhi Y, Figueredo J, Calcedo R et al. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat Med 2006; 12: 967-971.
90. Thomas CE, Storm TA, Huang Z, Kay MA. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol 2004; 78: 3110-3122.
91. Wang Z, Allen JM, Riddell SR, Gregorevic P, Storb R, Tapscott SJ et al. Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther 2007; 18: 18-26.
92. Wang Z, Kuhr CS, Allen JM, Blankinship M, Gregorevic P, Chamberlain JS et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 2007; 15: 1160-1166.
93. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A et al Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24: 257-261.
94. Nguyen DH, Hurtado-Ziola N, Gagneux P, Varki A. Loss of Siglec expression on T lymphocytes during human evolution. Proc Natl Acad Sci USA 2006; 103: 7765-7770.
95. High KA. Update on progress and hurdles in novel genetic therapies for hemophilia. Hematology Am Soc Hematol Educ Program 2007; 2007 466-472.